Everand Logo

Welcome to Everand!

  • STAT

    Vertex’s latest cystic fibrosis drug reports strong sales in first quarter since approval

    Vertex Pharmaceuticals’ latest cystic fibrosis drug — the Boston biotech’s third product to reach the market — is off to a strong commercial start.
    by Adam Feuerstein Apr 26, 2018 1 minute

    Vertex Pharmaceuticals’ (VRTX) latest cystic fibrosis drug — the Boston biotech’s third product to reach the market — is off to a strong commercial start.

    Sales of the new Vertex drug, marketed under

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min readCrime & Violence
    STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
    A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
    STAT2 min read
    STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
    A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
    An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.

    Related Books & Audiobooks